FDA Issues Guidance on Lot Distribution Reports for Biologics
Guidance provides labeling standards and an implementation guide for electronic submission of lot distribution reports.
FDA has issued a guidance document on how manufacturers of products under biologics license applications (BLAs) should electronically submit lot distribution reports (LDRs). Title 21 of the Code of Federal Regulations 600.81 requires that LDRs be submitted to FDA in an electronic format for FDA to process, review, and archive.
The guidance document creates the Structured Product Labeling (SPL) standard and vocabulary for electronic submission of LDRs as well as provides an implementation guide and validation procedures. FDA recommends manufacturers use the same message exchange format currently used for registration and drug product listing.
The guidance also states that FDA will link the Center for Biologics Evaluation and Research’s lot distribution database with FDA’s Adverse Event Reporting System and Vaccine Adverse Reporting System databases.
Source: FDA.gov
EMA Recommends Imfinzi-Based Perioperative Regimen for Treating Resectable NSCLC
March 10th 2025The committee’s recommendation is based on results from a Phase III trial in which Imfinzi demonstrated a reduced risk of recurrence, progression, or death by 32% compared to neoadjuvant chemotherapy alone.
International Women’s Day 2025: A Promising Future for Gender Diversity in Pharma
March 8th 2025In an interview with BioPharm International®, Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
